Pharmaceuticals

Ayr Wellness Inc.

Ayr Wellness Inc. released FY2025 Q1 earnings on September 12 (EST), actual revenue USD 107.31 M (forecast USD 109.4 M), actual EPS USD -0.4892

Ayr Wellness Inc. released FY2024 Q4 earnings during market hours on March 6 (EST), actual revenue 113.96 M USD (forecast 114.3 M USD), actual EPS -1.4027 USD

Ayr Wellness Inc. released FY2024 annual earnings on March 6 During-Market (EST), actual revenue 463.63 M USD (forecast 463.98 M USD), actual EPS -3.2419 USD

Ayr Wellness Inc. to Release FY2024 Q4 Earnings on March 6 During-Market EST, Forecast Revenue 114.08 M USD

Ayr Wellness Inc. released FY2024 Q3 earnings on November 13 Pre-Market (EST), actual revenue 114.33 MUSD (forecast 121.02 MUSD), actual EPS -0.4408 USD

Ayr Wellness Inc. released its Q3 2024 earnings on November 13, 2024 (EST), with actual revenue of 349.68M USD and EPS of -1.864

Ayr Wellness Inc. to Release FY2024 Q3 Earnings on November 13, Pre-Market EST; Forecast Revenue 121.02 M USD

AYR Wellness Inc. Obtains Conditional Approval for Medical Cannabis Business in Virginia

AYR Wellness Inc. Expands Cannabis Dispensaries in Florida

AYR Wellness announces Q2 2024 financial results

Resignation of Jonathan Sandelman, Director and CEO of Ayr Wellness Inc.

Increase in short positions for Ayr Wellness Inc.

Sobr Safe

Omeros

Northann

AMC Robotics

Euda Health

Dynavax Tech

Multi Ways

Indaptus Therapeutics

Sidus Space

Kandal M Venture

Eli Lilly

Roche

ROCHE HOLDINGS AG

Astrazeneca

NOVARTIS AG

Novo Nordisk AS

Chugai Pharmaceutical

UCB S.A.

Daiichi Sankyo

Otsuka Pharmaceutical

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap